Study of progesterone for the prevention of preterm birth in twins (STOPPIT) : findings from a trial-based cost-effectiveness analysis
Eddama, O., Petrou, Stavros, Regier, Dean A., Norrie, John, MacLennan, Graeme, Mackenzie, F. and Norman, Jane E.. (2010) Study of progesterone for the prevention of preterm birth in twins (STOPPIT) : findings from a trial-based cost-effectiveness analysis. International Journal of Technology Assessment in Health Care, Vol.26 (No.02). pp. 141-148. ISSN 0266-4623Full text not available from this repository.
Official URL: http://dx.doi.org/10.1017/S0266462310000036
Objectives: Preterm birth contributes to a range of healthcare problems amongst infants surmounting to sizeable healthcare costs. Twin pregnancies are at particular risk of preterm birth. The objective of this study was to assess the cost-effectiveness of vaginal progesterone gel for the prevention of preterm birth in twin pregnancies. Methods: An economic evaluation was conducted alongside a randomized placebo controlled trial (the STOPPIT trial) of vaginal progesterone gel for the prevention of preterm birth in twin pregnancies. Five hundred women were recruited from nine maternity hospitals in the United Kingdom. The outcomes of the economic evaluation were presented in terms of net benefit statistics, cost-effectiveness acceptability curves, generated using the nonparametric bootstrap method, and the expected value of perfect information. Results: Mean health service costs between the period of randomization and discharge for mother and infant were £28,031 in the progesterone group and £25,972 in the placebo group, generating a mean nonsignificant cost difference of £2,059 (bootstrap mean cost difference £2,334; 95 percent confidence interval: −£5,023, £9,142; p = .33). The probability of progesterone being cost-effective was 20 percent at a willingness to pay threshold of £30,000 per preterm birth prevented. There is little economic justification for conducting further research into the use of vaginal progesterone gel in twin pregnancies for the prevention of preterm birth. Conclusions: Further studies of preventive interventions for preterm birth more generally are required given the scale of the clinical and economic burden of this condition. These studies should be sufficiently powered for economic endpoints and extend beyond hospital discharge.
|Item Type:||Journal Article|
|Subjects:||R Medicine > RA Public aspects of medicine
R Medicine > RJ Pediatrics
|Divisions:||Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School
|Library of Congress Subject Headings (LCSH):||Progesterone -- Research, Premature labor -- Prevention, Medical economics, Twins, Placebos (Medicine), Clinical trial|
|Journal or Publication Title:||International Journal of Technology Assessment in Health Care|
|Publisher:||Cambridge University Press|
|Page Range:||pp. 141-148|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)